UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 441

Sortiert nach

Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis

Frontiers in oncology, 2020-02, Vol.10, p.91-91

2020

Volltextzugriff (PDF)

PB2017: CLINICAL OUTCOMES BY SF3B1 MUTATION STATUS IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES RETREATED WITH ERYTHROPOIESIS-STIMULATING AGENTS

HemaSphere, 2023-08, Vol.7 (S3), p.e20066a9

2023

Volltextzugriff (PDF)

Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies

Journal of hematology and oncology, 2012-12, Vol.5 (1), p.75-75, Article 75

2012

Volltextzugriff (PDF)

Carfilzomib: A second-generation proteasome inhibitor for the treatment of multiple myeloma

American journal of health-system pharmacy, 2015-03, Vol.72 (5), p.353-360

2015

Volltextzugriff (PDF)

Angiosarcoma treated successfully with anti-PD-1 therapy - a case report

Journal for immunotherapy of cancer, 2017-07, Vol.5 (1), p.58-58, Article 58

2017

Volltextzugriff (PDF)

Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review

Critical reviews in oncology/hematology, 2018-05, Vol.125, p.1-11

2018

Volltextzugriff (PDF)

Potential application and prevalence of the CD30 (Ki-1) antigen among solid tumors: A focus review of the literature

Critical reviews in oncology/hematology, 2017-05, Vol.113, p.8-17

2017

Volltextzugriff (PDF)

National survey on the effect of oncology drug shortages on cancer care

American journal of health-system pharmacy, 2013-04, Vol.70 (7), p.609-617

2013

Volltextzugriff (PDF)

Eribulin mesylate: A novel halichondrin B analogue for the treatment of metastatic breast cancer

American journal of health-system pharmacy, 2012-05, Vol.69 (9), p.745-755

2012

Volltextzugriff (PDF)

Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer

Journal of medical economics, 2017-04, Vol.20 (4), p.345-352

2017

Volltextzugriff (PDF)

Waldenström Macroglobulinemia: Review of Pathogenesis and Management

Clinical lymphoma, myeloma and leukemia, 2017-05, Vol.17 (5), p.252-262

2017

Volltextzugriff (PDF)

Retrospective real-world meta-analysis of high-risk major bleeding as a primary safety outcome in cancer patients receiving therapeutic anticoagulation

Thrombosis update, 2022-12, Vol.9, p.100121, Article 100121

2022

Volltextzugriff (PDF)

Treatment patterns and outcomes with luspatercept in patients with lower‐risk myelodysplastic syndromes: A retrospective US cohort analysis

HemaSphere, 2024-01, Vol.8 (1), p.e38-n/a

2024

Volltextzugriff (PDF)

Tocilizumab for steroid refractory acute graft-versus-host disease

Leukemia & lymphoma, 2016-01, Vol.57 (1), p.81-85

2016

Volltextzugriff (PDF)

Sustained response to pembrolizumab in recurrent perivascular epithelioid cell tumor with elevated expression of programmed death ligand: a case report

Journal of medical case reports, 2021-07, Vol.15 (1), p.1-400, Article 400

2021

Volltextzugriff (PDF)

P515: A REAL‐WORLD EVALUATION OF TREATMENT PATTERNS AND OUTCOMES OF ACUTE MYELOID LEUKEMIA INDUCTION THERAPIES IN THE COMMUNITY SETTING

HemaSphere, 2023-08, Vol.7 (S3), p.e682228c-n/a

2023

Volltextzugriff (PDF)

P589: IMPLICATIONS OF REGISTRY DATA FOR ACUTE MYELOID LEUKEMIA (AML) TREATMENT AND CARE DURING THE COVID‐19 PANDEMIC

HemaSphere, 2023-08, Vol.7 (S3), p.e5950536-n/a

2023

Volltextzugriff (PDF)

P733: TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH LOWER‐RISK MYELODYSPLASTIC SYNDROMES RECEIVING LUSPATERCEPT IN ROUTINE CLINICAL PRACTICE IN THE UNITED STATES

HemaSphere, 2023-08, Vol.7 (S3), p.e648138a-n/a

2023

Volltextzugriff (PDF)

Association of immune-checkpoint inhibitors and the risk of immune-related colitis among elderly patients with advanced melanoma: real-world evidence from the SEER–Medicare database

Therapeutic advances in drug safety, 2021, Vol.12, p.2042098621991279-2042098621991279

2021

Volltextzugriff (PDF)

A retrospective review of fall risk factors in the bone marrow transplant inpatient service

Journal of oncology pharmacy practice, 2018-06, Vol.24 (4), p.272-280

2018

Volltextzugriff (PDF)

Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML

International journal of hematology, 2014-03, Vol.99 (3), p.272-278

2014

Volltextzugriff (PDF)

Impact of Treatment Sequencing on Outcomes and Costs in Relapsed Follicular or Other Low Grade B-Cell Non-Hodgkin Lymphoma - Results of an Evidence-Based Budget Impact Model

Blood, 2020-11, Vol.136 (Supplement 1), p.14-15

2020

Volltextzugriff (PDF)

Cost-Effectiveness Analyses of First Line Ibrutinib Versus Acalabrutinib Versus Zanubrutinib Followed By Second Line Venetoclax Plus Rituximab in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients

Blood, 2022-11, Vol.140 (Supplement 1), p.2155-2156

2022

Volltextzugriff (PDF)

The Emerging Role of Oral Oncolytics

Oncology issues, 2020-01, Vol.35 (1), p.3-3

McBride, Ali

2020

Volltextzugriff (PDF)

Pentoxifylline and vitamin E drug compliance after adjuvant breast radiation therapy

Advances in radiation oncology, 2018-01, Vol.3 (1), p.19-24

2018

Volltextzugriff (PDF)

1 – 25 von 441

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(390)
Mit Volltextzugriff
(383)

Publikationsform

Sprache

Englisch
(441)
Japanisch
(17)

Erscheinungsjahr

n.n

Thema

Science & Technology
(175)
Life Sciences & Biomedicine
(166)
Humans
(132)
Oncology
(63)
Female
(48)
Male
(47)
Middle Aged
(35)
Pharmacology & Pharmacy
(34)
Hematology
(33)
Health Care Sciences & Services
(30)
Adult
(28)
Chemotherapy
(25)
Aged
(24)
General & Internal Medicine
(24)
Medicine, General & Internal
(23)
Antineoplastic Agents - Therapeutic Use
(20)
Cancer
(20)
Hematology, Oncology And Palliative Medicine
(20)
Patients
(19)
Retrospective Studies
(19)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis

PB2017: CLINICAL OUTCOMES BY SF3B1 MUTATION STATUS IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES RETREATED WITH ERYTHROPOIESIS-STIMULATING AGENTS

Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies

Carfilzomib: A second-generation proteasome inhibitor for the treatment of multiple myeloma

Angiosarcoma treated successfully with anti-PD-1 therapy - a case report

Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review

Potential application and prevalence of the CD30 (Ki-1) antigen among solid tumors: A focus review of the literature

National survey on the effect of oncology drug shortages on cancer care

Eribulin mesylate: A novel halichondrin B analogue for the treatment of metastatic breast cancer

Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer

Waldenström Macroglobulinemia: Review of Pathogenesis and Management

Retrospective real-world meta-analysis of high-risk major bleeding as a primary safety outcome in cancer patients receiving therapeutic anticoagulation

Treatment patterns and outcomes with luspatercept in patients with lower‐risk myelodysplastic syndromes: A retrospective US cohort analysis

Tocilizumab for steroid refractory acute graft-versus-host disease

Sustained response to pembrolizumab in recurrent perivascular epithelioid cell tumor with elevated expression of programmed death ligand: a case report

P515: A REAL‐WORLD EVALUATION OF TREATMENT PATTERNS AND OUTCOMES OF ACUTE MYELOID LEUKEMIA INDUCTION THERAPIES IN THE COMMUNITY SETTING

P589: IMPLICATIONS OF REGISTRY DATA FOR ACUTE MYELOID LEUKEMIA (AML) TREATMENT AND CARE DURING THE COVID‐19 PANDEMIC

P733: TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH LOWER‐RISK MYELODYSPLASTIC SYNDROMES RECEIVING LUSPATERCEPT IN ROUTINE CLINICAL PRACTICE IN THE UNITED STATES

Association of immune-checkpoint inhibitors and the risk of immune-related colitis among elderly patients with advanced melanoma: real-world evidence from the SEER–Medicare database

A retrospective review of fall risk factors in the bone marrow transplant inpatient service

Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML

Impact of Treatment Sequencing on Outcomes and Costs in Relapsed Follicular or Other Low Grade B-Cell Non-Hodgkin Lymphoma - Results of an Evidence-Based Budget Impact Model

Cost-Effectiveness Analyses of First Line Ibrutinib Versus Acalabrutinib Versus Zanubrutinib Followed By Second Line Venetoclax Plus Rituximab in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients

The Emerging Role of Oral Oncolytics

Pentoxifylline and vitamin E drug compliance after adjuvant breast radiation therapy

Suchergebnisse filtern